Harrow announced it will report Q4 and full-year 2025 financial results on March 2, 2026, with a conference call scheduled for March 3, 2026. The company reaffirmed its 2025 full-year revenue guidance of $270-$280 million, indicating strong growth. Harrow is expanding its commercial footprint across multiple product lines including VEVYE, IHEEZO, and TRIESENCE.

Harrow reaffirmed its 2025 revenue guidance of $270-280 million and announced multiple growth initiatives including doubling its VEVYE sales force, expanding IHEEZO to office-based settings, and doubling TRIESENCE's surgical sales force. The company launched the OneHarrow initiative to unify branding, promoted Patrick W. Sullivan to Chief Commercial Officer, and advanced MELT-300 and MELT-210 toward NDA filings. ImprimisRx settled regulatory matters with California and exited the state market.

Penn Capital Management sold 1.6 million shares of BGC Group in Q3, reducing its stake to $5.9 million, despite the company reporting record quarterly revenue of $736.8 million, up 31% year-over-year.

Harrow Inc. announced the acquisition of Melt Pharmaceuticals, a clinical-stage company developing a non-opioid sedation tablet (MELT-300) for medical procedures. The company plans to submit a New Drug Application to the FDA in 2027, targeting a U.S. launch in 2028.

Harrow plans to acquire Melt Pharmaceuticals for its MELT-300 sedation therapy, a non-opioid sublingual medication designed to provide rapid sedation for medical procedures. The acquisition aims to expand Harrow's procedural sedation market presence and offer an alternative to traditional IV sedation.

Harrow is raising $250 million through senior unsecured notes due in 2030, with plans to repay existing debt and potentially fund future business development opportunities.

Harrow is issuing $250 million in senior unsecured notes due 2030 and entering a new $40 million revolving credit facility with Fifth Third Bank. The company plans to use proceeds to repay existing debt and redeem outstanding senior notes.

Pomerantz LLP is investigating potential securities fraud at Harrow, Inc. after the company missed financial estimates in Q1 2025, causing its stock price to drop 4.07%.

Nicox announced that the last patient has completed the final visit in the Whistler Phase 3b clinical trial for its lead product candidate NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The results of the Denali Phase 3 trial are also expected in Q3 2025.

U.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.

Nicox presented additional analysis from the NCX 470 Mont Blanc Phase 3 trial, showing that more patients on NCX 470 achieved an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost. The company also provided an update on the development of NCX 470, including plans for a U.S. New Drug Application submission targeted in H1 2026.

Nicox, a specialty ophthalmology company, announces a poster presentation at the American Glaucoma Society Congress and participation in several key ophthalmology and finance conferences in the first half of 2025.